Liraglutide API Powder

High-Purity Synthetic Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist

Technical Data Sheet

CAS Number	204656-20-2
Purity (HPLC)	≥99.0%
Molecular Formula	C₁₇₂H₂₆₅N₄₃O₅₁
Molecular Weight	3751.2 Da
Peptide Content	≥85.0%
Appearance	White to off-white lyophilized powder
Storage Condition	-20°C ± 5°C, light-protected

Product Introduction

Shaanxi Sunrise Pharmaceutical Co., Ltd. specializes in the manufacturing of ultra-high purity Liraglutide API (CAS 204656-20-2). Liraglutide is a synthetic polypeptide with 97% homology to human GLP-1. Our manufacturing process ensures exceptional stability and consistency, making it a reliable choice for pharmaceutical-grade research and weight management formulation development.

Pharmacological Actions

🩸

Glycemic Control

Stimulates glucose-dependent insulin secretion while suppressing excess glucagon release.

🍽️

Appetite Regulation

Acts on the central nervous system to increase satiety and slow gastric emptying.

🛡️

Cardio-Protection

Clinical research indicates protective effects against major adverse cardiovascular events.

Mechanism of Action

Receptor Activation: Liraglutide binds to GLP-1 receptors, initiating intracellular signaling to promote insulin synthesis.
Albumin Binding: A C-16 fatty acid side chain allows reversible binding to albumin, preventing rapid renal clearance.
Half-life Extension: Structural modification extends the half-life to approx. 13 hours, supporting once-daily dosing research.

Popular FAQ

Q: What makes Shaanxi Sunrise Liraglutide API unique?

A: Our API achieves ≥99.0% purity with extremely low residual solvents and related peptide impurities, verified by HPLC and Mass Spec.

Q: Is this product intended for direct human use?

A: No. This product is a high-standard raw material API intended strictly for industrial use, formulation development, or laboratory research.

SAFETY & USAGE DECLARATION:

Shaanxi Sunrise Pharmaceutical Co., Ltd. provides Liraglutide for professional research and manufacturing purposes only. Purchasers must provide institutional verification.